COMPANY:

Stilla Technologies

"Bio-Rad Laboratories, Inc...today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies (“Stilla”). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025."

"Stilla Technologies...announce a strategic partnership with Niba Labs, an expert laboratory specializing in developing and testing digital PCR assays for gene therapy product...This collaboration will focus on the development of advanced digital PCR assays tailored to the needs of the gene therapy market. The Crystal Digital PCR® assays leveraging the Crystal Flex Probes technology will contribute to the scientific community by providing new solutions for viral vector characterization and gene therapy product optimization."

"Digital PCR system developer Stilla Technologies...signed a strategic distribution partnership for the US with Radnor, Pennsylvania-based Avantor. Financial terms of the deal were not disclosed."

"Stilla Technologies...announced it has closed a $26.5 million Series C financing. The financing was led by a the venture fund CLIFF with its main investors Yuzi Investment Holding Group (Yuzi) and Tus-Holdings, together with the participation of existing investors Illumina Ventures, Kurma Partners, PSSF, IdInvest, BNP Paribas Development and LBO France."

"Stilla Technologies...announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR™ platform, the naica® system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples. Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute quantitation of nucleic acids from genetic mutations found across a widespread range of oncological indications."

"Stilla Technologies and Atila BioSystems today announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system (Stilla Technologies). The digital PCR kits, optimized specifically for use with the 6-color naica® system, will be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples taken from patients with high-occurring cancer indications such as breast, lung, melanoma, prostate, and colorectal cancers....The co-labeled digital PCR kits will be promoted globally by Atila and Stilla and will be designed For Research Use Only (RUO) applications."

"Stilla Technologies, the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell® systems and digital PCR on the six-color naica® system. With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery."

"Stilla Technologies announced on Tuesday that it has formed partnerships with 12 new distributors in Europe, the Middle East, and Africa. The agreements allow distribution of the firm's six-color Naica digital PCR platform as well as microfluidic chips and reagents...The applications for the six-color Naica system include cancer and liquid biopsy studies, cell and gene therapies, and infectious disease detection."

"Stilla Technologies announced on Tuesday it has raised €31.3 million ($35.2 million) in new funding. The Paris-based firm will use the funds to expand its global commercial presence and develop its next-generation digital PCR platform."